Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

Marilia Brito Gomes, Carlos Antonio Negrato, Marilia Brito Gomes, Carlos Antonio Negrato

Abstract

Alpha-lipoic acid is a naturally occurring substance, essential for the function of different enzymes that take part in mitochondria's oxidative metabolism. It is believed that alpha-lipoic acid or its reduced form, dihydrolipoic acid have many biochemical functions acting as biological antioxidants, as metal chelators, reducers of the oxidized forms of other antioxidant agents such as vitamin C and E, and modulator of the signaling transduction of several pathways. These above-mentioned actions have been shown in experimental studies emphasizing the use of alpha-lipoic acid as a potential therapeutic agent for many chronic diseases with great epidemiological as well economic and social impact such as brain diseases and cognitive dysfunctions like Alzheimer disease, obesity, nonalcoholic fatty liver disease, burning mouth syndrome, cardiovascular disease, hypertension, some types of cancer, glaucoma and osteoporosis. Many conflicting data have been found concerning the clinical use of alpha-lipoic acid in the treatment of diabetes and of diabetes-related chronic complications such as retinopathy, nephropathy, neuropathy, wound healing and diabetic cardiovascular autonomic neuropathy. The most frequent clinical condition in which alpha-lipoic acid has been studied was in the management of diabetic peripheral neuropathy in patients with type 1 as well type 2 diabetes. Considering that oxidative stress, a imbalance between pro and antioxidants with excessive production of reactive oxygen species, is a factor in the development of many diseases and that alpha-lipoic acid, a natural thiol antioxidant, has been shown to have beneficial effects on oxidative stress parameters in various tissues we wrote this article in order to make an up-to-date review of current thinking regarding alpha-lipoic acid and its use as an antioxidant drug therapy for a myriad of diseases that could have potential benefits from its use.

Keywords: Alpha-lipoic acid; Biochemical action; Chronic diseases; Diabetes mellitus.

Figures

Figure 1
Figure 1
Enantiomers (R and S) of lipoic acid.
Figure 2
Figure 2
Chemical structure of alpha lipoic acid (ALA) and its reduced from dihydrolipoic acid (DHLA).

References

    1. Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic Acid. Front Pharmacol. 2011;2:69. doi: 10.3389/fphar.2011.00069.
    1. Reed LJ. From lipoic acid to multi-enzyme complexes. Protein Sci. 1998;7(1):220–224. doi: 10.1002/pro.5560070125.
    1. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–1160. doi: 10.1016/j.bbagen.2009.07.026.
    1. Snell EE, Strong FM, Peterson WH. Growth factor for Fractionation and properties of an accessory factor for lactic acid bacteria. Bichem J. 1937;31:1789–1799.
    1. Reed LJ, De Busk BG, Gunsalus IC, Hornberger CS. Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science. 1951;114:93–94. doi: 10.1126/science.114.2952.93.
    1. Bock E, Schneeweiss J. Ein Beitrag zur Therapie der neuropathia diabetic. Munchner Med Wochenschrift. 1959;43:1911–1912.
    1. Wray DW, Nishyyama SK, Harris RA, Zhao J, McDaniel J, Fjeldstad AS, Witman MA, Ives SJ, Barrett-O’Keefe Z, Richardson RS. Acute reversal of endothelial dysfunction in the elderly following antioxidant consumption. Hypertension. 2012;59:818–824. doi: 10.1161/HYPERTENSIONAHA.111.189456.
    1. McNeilly AM, Davison GW, Murphy MH, Nadeem N, Trinick T, Duly E, Novials A, McEneny J. Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. Lipids Health Dis. 2011;10:217. doi: 10.1186/1476-511X-10-217.
    1. Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation. 2008;117(3):421–428. doi: 10.1161/CIRCULATIONAHA.107.725275.
    1. Ying Z, Kherada N, Farrar B, Kampfrath T, Chung Y, Simonetti O, Deiuliis J, Desikan R, Khan B, Villamena F, Sun Q, Parthasarathy S, Rajagopalan S. Lipoic acid effects on established atherosclerosis. Life Sci. 2010;86(3–4):95–102. doi: 10.1016/j.lfs.2009.11.009.
    1. Ziegler D, Reljanovic M, Mehnert H, Gries FA. α Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107:421–430. doi: 10.1055/s-0029-1212132.
    1. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17:888–895. doi: 10.1016/S0899-9007(01)00658-X.
    1. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. 2000;18(5):567–573. doi: 10.1097/00004872-200018050-00009.
    1. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G. Lipoic acidi and n-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis. 2007;12:195–206.
    1. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A. 2011;155A:1939–1948. doi: 10.1002/ajmg.a.34114.
    1. Al Abdan M. Alfa-lipoic acid controls tumor growth and modulates hepatic redox state in Ehrlich-ascites-carcinoma-bearing mice. Scientific World Journal. 2012;2012:509838. doi: 10.1100/2012/509838.
    1. Szelag M, Mikulski D, Molski M. Quantum-chemical investigation of the structure and the antioxidant properties of α-lipoic acid and its metabolites. J Mol Model. 2012;18:2907–2916. doi: 10.1007/s00894-011-1306-y.
    1. Padmalayam I, Hasham S, Saxena U, Pillarisetti S. Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes. 2009;58:600–608. doi: 10.2337/db08-0473.
    1. McLain AL, Cormier PJ, Kinter M, Szweda LI. Glutathionylation of α-ketoglutarate dehydrogenase: the chemical nature and relative susceptibility of the cofactor lipoic acid to modification. Free Radic Biol Med. 2013;61C:161–169. doi: 10.1016/j.freeradbiomed.2013.03.020.
    1. Hassan BH, Cronan JE. Protein-protein interactions in assembly of lipoic acid on the 2-oxoacid dehydrogenases of aerobic metabolism. J Biol Chem. 2011;286:8263–8276. doi: 10.1074/jbc.M110.194191.
    1. Moini H, Tirosh O, Park YC, Cho KJ, Packer L. R-alpha-lipoic acid action on cell redox status, the insulin receptor, and glucose uptake in 3T3-L1 adipocytes. Arch Biochem Biophys. 2002;397(2):384–391. doi: 10.1006/abbi.2001.2680.
    1. A-Vadlapudi AD, Vadlapatla RK, Mitra AK. Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. Curr Drug Targets. 2012;13:994–1003. doi: 10.2174/138945012800675650.
    1. Scott BC, Aruoma OI, Evans PJ, O’Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B. Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res. 1994;20(2):119–133. doi: 10.3109/10715769409147509.
    1. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med. 1995;19(2):227–250. doi: 10.1016/0891-5849(95)00017-R.
    1. Trujillo M, Radi R. Peroxynitrite reaction with the reduced and the oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with thiols. Arch of Biochem and Biophys. 2002;397(1):91–98. doi: 10.1006/abbi.2001.2619.
    1. Vriesman MF, Haenen GR, Westerveld GJ, Paquay JB, Voss HP, Bast A. A method for measuring nitric oxide radical scavenging activity. Scavenging properties of sulfur-containing compounds. Pharm World Sci. 1997;19(6):283–286. doi: 10.1023/A:1008601327920.
    1. Suzuki YJ, Tsuchiya M, Packer L. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun. 1991;15(5):255–263. doi: 10.3109/10715769109105221.
    1. Suzuki YJ, Tsuchiya M, Packer L. Antioxidant activities of dihydrolipoic acid and its structural homologues. Free Radic Res Commun. 1993;18(2):115–122. doi: 10.3109/10715769309147348.
    1. Devasagayam TP, Di Mascio P, Kaiser S, Sies H. Singlet oxygen induced single-strand breaks in plasmid pBR322 DNA: the enhancing effect of thiols. Biochim Biophys Acta. 1991;1088(3):409–412. doi: 10.1016/0167-4781(91)90133-7.
    1. Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R, Packer L. Dihydrolipoic acid–a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem Pharmacol. 1992;44(8):1637–1649. doi: 10.1016/0006-2952(92)90482-X.
    1. Haenen GR, Bast A. Scavenging of hypochlorous acid by lipoic acid. Biochem Pharmacol. 1991;42(11):2244–2246. doi: 10.1016/0006-2952(91)90363-A.
    1. Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R. Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: a critical role for amino acids. J Endocrinol. 2012;214(1):11–20. doi: 10.1530/JOE-12-0072.
    1. Koriyama Y, Nakayama Y, Matsugo S, Kato S. Protective effect of lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Brain Res. 2013;1499:145–157. doi: 10.1016/j.brainres.2012.12.041.
    1. Wilking M, Ndiaye M, Mukhtar H, Ahmad N. Circadian rythms connections to oxidative stress: implications for human health. Antioxid Redox Signal. 2013;19:192–208. doi: 10.1089/ars.2012.4889.
    1. Dicter N, Madar Z, Tirosh O. Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J Nutr. 2002;132(10):3001–3006.
    1. Rouchette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C. Direct and indirect antioxidant properties of α -lipoic acid. Mol Nutr Food Res. 2013;57:114–125. doi: 10.1002/mnfr.201200608.
    1. Moini H, Packer L, Saris N-E. Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol. 2002;182:84–90. doi: 10.1006/taap.2002.9437.
    1. Zhang DD, Lo S-C, Cross JV, Templeton DJ, Hannink M. keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24:10941–10953. doi: 10.1128/MCB.24.24.10941-10953.2004.
    1. Dinkova-kostova AT, Talalay P. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res. 2008;52:S128–S138.
    1. Frizzell N, Baynes JW. Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem. 2013;5(10):1075–1078. doi: 10.4155/fmc.13.73.
    1. Ou P, Tritscheler HJ, Wolff SP. Thioctic (lipoic acid): a therapeutical metal-chelating antioxidant? Biochem Pharmacol. 1995;50:123–126. doi: 10.1016/0006-2952(95)00116-H.
    1. Bast A, Haenen GR. Lipoic acid: a multifunctional antioxidant. Biofactors. 2003;17(1–4):207–213. doi: 10.1002/biof.5520170120.
    1. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004;11(9):1135–1146. doi: 10.2174/0929867043365387.
    1. Yaworsky K, Somwar R, Ramlal T, Tritschler HJ, Klip A. Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Diabetologia. 2000;43(3):294–303. doi: 10.1007/s001250050047.
    1. Estrada DE, Ewart HS, Tsakiridis T, Volchuk A, Ramlal T, Tritschler H, Klip A. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes. 1996;45(12):1798–1804. doi: 10.2337/diab.45.12.1798.
    1. Henriksen EJ, Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ. Stimulation by alpha-lipoic acid of glucose transport activity in skeletal muscle of lean and obese Zucker rats. Life Sci. 1997;61(8):805–812. doi: 10.1016/S0024-3205(97)00562-6.
    1. Yamamoto Y, Gaynor RB. Therapeutical potential of inhibition of the NFkb pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135–142. doi: 10.1172/JCI11914.
    1. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205(10):2409–2417. doi: 10.1084/jem.20081188.
    1. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes. 1997;46(9):1481–1490. doi: 10.2337/diab.46.9.1481.
    1. Ying Z, Kampfrath T, Sun Q, Parthasarathy S, Rajagopalan S. Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function. Inflamm Res. 2011;60(3):219–225. doi: 10.1007/s00011-010-0256-7.
    1. Zembron-Lacny A, Gajeswski M, Naczac M, Dziewiecka H, Siatkkowski I. Physical activity and alpha-lipoic acid modulate inflammatory response through changes in thiol redox status. J Physiolo. 2013;69:397–404.
    1. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005;111(3):343–348. doi: 10.1161/01.CIR.0000153272.48711.B9.
    1. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025–1078. doi: 10.1152/physrev.00011.2008.
    1. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–1174. doi: 10.1172/JCI13505.
    1. Shen QW, Zhu MJ, Tong J, Ren J, Du M. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Am J Physiol Cell Physiol. 2007;293(4):C1395–C1403. doi: 10.1152/ajpcell.00115.2007.
    1. Wang Y, Li X, Guo Y, Chan L, Guan X. Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Metabolism. 2010;59(7):967–976. doi: 10.1016/j.metabol.2009.10.018.
    1. Targonsky ED, Dai F, Koshkin V, Karaman GT, Gyulkhandanyan AV, Zhang Y, Chan CB, Wheeler MB. Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia. 2006;49(7):1587–1598. doi: 10.1007/s00125-006-0265-9.
    1. Koh G, Yang EJ, Kim MK, Lee SA, Lee DH. Biol Pharm Bull. 2013. Alpha-lipoic acid treatment reverses 2-deoxy-D-ribose-induced oxidative damage and suppression of insulin expression in pancreatic β-cells.
    1. Ramamurthy S, Ronnet G. AMP-activated protein kinase (AMPK) and energy sensing in the brain. Exp Neurobiol. 2012;21(2):52–60. doi: 10.5607/en.2012.21.2.52.
    1. Blazquez C, Geelen MJ, Velasco G, Guzmán M. The AMP activated protein kinase prevents ceramide synthesis de novo and astrocytes. FEBS Lett. 2001;489(2–3):149–153. doi: 10.1016/S0014-5793(01)02089-0.
    1. Nakatsu Y, Kotake Y, Hino A, Ohta S. Activation of AMO-activated protein kinase by tributyltin induces neuronal cell death. Toxicol Appl Pharmacol. 2008;230(3):358–363. doi: 10.1016/j.taap.2008.03.021.
    1. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med. 2004;10(7):727–733. doi: 10.1038/nm1061.
    1. Seo EY, Ha AW, Kim WK. α lipoic acid reduced weight gain and improved lipid profile in rats fed with high fat diet. Nutr Res Pract. 2012;6:195–200. doi: 10.4162/nrp.2012.6.3.195.
    1. Tomassoni D, Amenta F, Amantini C, Farfariello V, Di Cesare ML, Nwankwo IE, Marini C, Tayebati SK. Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury. Int J Mol Sci. 2013;14(3):4580–4595. doi: 10.3390/ijms14034580.
    1. Cho KJ, Moon HE, Moini H, Packer L, Yoon DY, Chung AS. Alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways. J Biol Chem. 2003;278(37):34823–34833. doi: 10.1074/jbc.M210747200.
    1. Wang Y, Dong W, Ding X, Wang F, Wang Y, Chen X, Yu L, Li X, Zhang A, Peng Y. Protective effect of α-lipoic acid on islet cells co-cultured with 3T3L1 adipocytes. Exp Ther Med. 2012;4(3):469–474.
    1. Tian YF, He CT, Chen YT, Hsieh PS. Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. World J Gastroenterol. 2013;19(18):2761–2771. doi: 10.3748/wjg.v19.i18.2761.
    1. Ong SL, Vohra H, Zhang Y, Sutton M, Whitworth JA. The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension. Oxid Med Cell Longev. 2013;2013:517045. doi: 10.1155/2013/517045.
    1. Li CJ, Lv L, Li H, Yu D. Cardiac fibrosis and dysfunctionin experimental diabetic cardiomyopathy are amelioreted by alpha-lipoic acid. Cardiovasc Diabetol. 2012;11:142. doi: 10.1186/1475-2840-11-142.
    1. Deng C, Sun Z, Tong G, Yi W, Ma L, Zhao B, Cheng L, Zhang J, Cao F, Yi D. α-Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PLoS One. 2013;8(3):e58371. doi: 10.1371/journal.pone.0058371.
    1. Yi X, Nickeleit V, James LR, Maeda N. α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. J Diabetes Complications. 2011;25(3):193–201. doi: 10.1016/j.jdiacomp.2010.07.004.
    1. Inman DM, Lambert WS, Calkins DJ, Horner PJ. α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS One. 2013;8(6):e65389. doi: 10.1371/journal.pone.0065389.
    1. Jha MK, Jeon S, Suk K. Pyruvate Dehydrogenase Kinases in the nervous system: their principal functions in Neuronal-glial metabolic interaction and Neuro-metabolic disorders. Curr Neuropharmacol. 2012;10:393–403. doi: 10.2174/1570159X11209040393.
    1. Carvalho C, Cardoso S, Correia SC, Santos RX, Santos MS, Baldeiras I, Oliveira CR, Moreira PI. Metabolic alterations induced by sucrose intake and Alzheimer’s disease promote similar brain mitochondrial abnormalities. Diabetes. 2012;61(5):1234–1242. doi: 10.2337/db11-1186.
    1. Maher PA, Schubert DR. Metabolic links between diabetes and Alzheimer’s disease. Expert Rev Neurother. 2009;9:617–630. doi: 10.1586/ern.09.18.
    1. Piau A, Nourhashémi F, Hein C, Caillaud C, Vellas B. Progress in the development of new drugs in Alzheimer’s disease. J Nutr Health Aging. 2011;15(1):45–57. doi: 10.1007/s12603-011-0012-x.
    1. Sancheti H, Akopian G, Yin F, Brinton RD, Walsh JP, Cadenas E. Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer’s disease. PLoS One. 2013;8:e69830. doi: 10.1371/journal.pone.0069830.
    1. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology. 2011;60(6):910–920. doi: 10.1016/j.neuropharm.2011.01.033.
    1. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease. Adv Drug Deliv Rev. 2008;60:1463–1470. doi: 10.1016/j.addr.2008.04.015.
    1. Hager K, Kenklies M, McAfoose J, Engel J, Münch G. Alpha-lipoic acid as a new treatment option for Alzheimer’s disease–a 48 months follow-up analysis. J Neural Transm Suppl. 2007;72:189–193. doi: 10.1007/978-3-211-73574-9_24.
    1. Cho JY, Um HS, Kang EB, Cho IH, Kim CH, Cho JS, Hwang DY. The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer’s disease in NSE/APPsw-transgenic mice. Int J Mol Med. 2010;25(3):337–346. doi: 10.3892/ijmm_00000350.
    1. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Alfredo Martínez J, Moreno-Aliaga MJ. Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats. Eur J Nutr. 2013;52(2):779–787. doi: 10.1007/s00394-012-0384-7.
    1. Deiuliis JA, Kampfrath T, Ying Z, Maiseyeu A, Rajagopalan S. Lipoic acid attenuates innate immune infiltration and activation in the visceral adipose tissue of obese insulin resistant mice. Lipids. 2011;46:1021–1032. doi: 10.1007/s11745-011-3603-8.
    1. Lamb RE, Goldstein BJ. Modulating an oxidative-inflmmatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Int J Clin Pract. 2008;62(7):1087–1095. doi: 10.1111/j.1742-1241.2008.01789.x.
    1. Xiao C, Giacca A, Lewis GF. Short-term oral α-lipoic acid does not prevent lipid-induced dysregulation of glucose homeostasis in obese and overweight nondiabetic men. Am J Physiol Endocrinol Metab. 2011;301:E736–E741. doi: 10.1152/ajpendo.00183.2011.
    1. Zhang Y, Han P, Wu N, He B, Lu Y, Li S, Liu Y, Zhao S, Liu L, Li Y. Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring) 2011;19(8):1647–1653. doi: 10.1038/oby.2011.121.
    1. Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, Kim DW, Kim MS, Park JY, Park KG, Lee HJ, Lee IK, Lim S, Jang HC, Lee KH, Lee KU. Effects of alpha-lipoic acid on body weight in obese subjects. Am J Med. 2011;124:85.e1–85.e8. doi: 10.1016/j.amjmed.2010.08.005.
    1. Ratliff JC, Palmese LB, Reutenauer EL, Tek C. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Clin Schizophr Relat Psychoses. 2013;7:1–13.
    1. Lean MEJ. Sibutramine: a review of clinical efficacy. In J Obes. 1997;21:30S–36S.
    1. Lazo M, Clark JM. The epidemiology of nonalcoolic faty liver disease: a global perspective. Semin Liver Dis. 2008;28:339–350. doi: 10.1055/s-0028-1091978.
    1. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100. doi: 10.1053/gast.2001.25540.
    1. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J Nutr Biochem. 2012;23(12):1676–1684. doi: 10.1016/j.jnutbio.2011.11.011.
    1. Jung TS, Kim SK, Shin HJ, Jeon BT, Hahm JR, Roh GS. α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats. Liver Int. 2012;32:1565–1573. doi: 10.1111/j.1478-3231.2012.02857.x.
    1. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity. 2012;20(10):1974–1983. doi: 10.1038/oby.2012.32.
    1. Chen WL, Kang CH, Wang SG, Lee HM. α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012;55(6):1824–1835. doi: 10.1007/s00125-012-2530-4.
    1. Chong ZZ, Shang YC, Wang S, Maiesse K. SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets. 2012;16:167–178. doi: 10.1517/14728222.2012.648926.
    1. Gurvits GE, Tan A. Burning mouth syndrome. World J Gastroenterol. 2013;7:665–672. doi: 10.3748/wjg.v19.i5.665.
    1. Cavalcanti DR, da Silveira FR. Alpha lipoic acid in burning mouth syndrome–a randomized double-blind placebo-controlled trial. J Oral Pathol Med. 2009;38:254–261. doi: 10.1111/j.1600-0714.2008.00735.x.
    1. Femiano F, Lanza A, Buonaiuto C, Gombos F, Nunziata M, Cuccurullo L, Cirillo N. Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:e22–e27. doi: 10.1016/j.tripleo.2007.07.030.
    1. Femiano F. Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Minerva Stomatol. 2002;51:405–409.
    1. Hu G, Jousilhati P, Qiao Q, Katoh S. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia. 2005;48:856–861. doi: 10.1007/s00125-005-1730-6.
    1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. doi: 10.1038/414813a.
    1. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL, Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism Antioxidant vitamin supplements and cardiovascular disease. Circulation. 2004;110(5):637–641. doi: 10.1161/01.CIR.0000137822.39831.F1.
    1. McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF, Jr, Vita JA. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007;9(4):249–255. doi: 10.1111/j.1524-6175.2007.06052.x.
    1. Durand M, Mach N. Alpha lipoic acid and its antioxidant against cancer and diseases of central sensitization. Nutr Hosp. 2013;28:1031–1038.
    1. Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 2013;335(2):472–478. doi: 10.1016/j.canlet.2013.03.008.
    1. Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, Senekowitsch-Schmidtke R. Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Cancer Biol Ther. 2012;13(14):1425–1435. doi: 10.4161/cbt.22003.
    1. Kim JI, Cho SR, Lee CM, Park ES, Kim KN, Kim HC, Lee HY. Induction of ER stress-mediated apoptosis by α-Lipoic Acid in A549 cell lines. Korean J Thorac Cardiovasc Surg. 2012;45(1):1–10. doi: 10.5090/kjtcs.2012.45.1.1.
    1. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003;37(2):213–223. doi: 10.1080/10715760303849.
    1. Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs. 2012;30:200–211. doi: 10.1007/s10637-010-9552-x.
    1. Diesel B, Kulhanek-Heinze S, Höltje M, Brandt B, Höltje HD, Vollmar AM, Kiemer AK. Alpha-lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Biochemistry. 2007;46(8):2146–2155. doi: 10.1021/bi602547m.
    1. Polat B, Halici Z, Cadirci E, Albayrak A, Karakus E, Bayir Y, Bilen H, Sahin A, Yuksel TN. Eur J Pharmacol. 2013. The effect of alpha-lipoic acid in ovariectomy and inflammation-mediated osteoporosis on the skeletal status of rat bone.
    1. Xiao Y, Cui J, Shi Y, Le G. Lipoic acid increases the expression of genes involved in bone formation in mice fed a high-fat diet. Nutr Res. 2011;31(4):309–317. doi: 10.1016/j.nutres.2011.03.013.
    1. Skyler J, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Ver. 2002;18:S21–S26. doi: 10.1002/dmrr.289.
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalences of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053. doi: 10.2337/diacare.27.5.1047.
    1. The Diabetes Control and Complications Trial Study Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with diabetes type 1. N Engl J Med. 2005;353:2643–2653. doi: 10.1056/NEJMoa052187.
    1. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405.
    1. Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, Savoldelli RD, Cobas RA, Coelho WS, Tschiedel B, Ramos AJ, Fonseca RM, Araujo NB, Almeida HG, Melo NH, Jezini DL, Negrato CA. Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Acta Diabetol. 2013;50(5):743–752. doi: 10.1007/s00592-012-0404-3.
    1. Gomes MB, Giannella-Neto D, Faria M, Tambascia MA, Fonseca RM, Rea RR, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Atala Dib S. Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multicenter study in Brazil. Rev Diabet Stud. 2006;3:82–87. doi: 10.1900/RDS.2006.3.82.
    1. American Diabetes Association Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31:596–615. doi: 10.2337/dc08-9017.
    1. Cobas RA, Ferraz MB, Matheus ASM, Tannus LRM, Negrato CA, Araújo LA, Dib SA, Gomes MB, Brazilian Type 1 Diabetes Study Group The cost of type 1 diabetes: a nationwide multicentre study in Brazil. Bull World Health Organ. 2013;91:434–440. doi: 10.2471/BLT.12.110387.
    1. Ceriello A, Sudhesh K, Piconi L, Esposito K, Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care. 2007;30(3):649–654. doi: 10.2337/dc06-2048.
    1. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diabetes Care. 2003;26(5):1374–1379. doi: 10.2337/diacare.26.5.1374.
    1. Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R. Plasma PAF–acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2009;85:61–68. doi: 10.1016/j.diabres.2009.04.016.
    1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100(10):1134–1146. doi: 10.1161/01.CIR.100.10.1134.
    1. van Vliet M, Van der Heyden JC, Diamant M, Von Rosenstiel IA, Schindhelm RK, Aanstoot HJ, Veeze HJ. Overweight is highly prevalent in children with type 1 diabetes and associates with cardiometabolic Risk. J Pediatr. 2010;156(6):923–929. doi: 10.1016/j.jpeds.2009.12.017.
    1. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52(1):1–8. doi: 10.2337/diabetes.52.1.1.
    1. Chang YC, Chuang LM. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am J Transl Res. 2010;2(3):316–331.
    1. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end- products: a review. Diabetologia. 2001;44(2):129–146. doi: 10.1007/s001250051591.
    1. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19(3):257–267. doi: 10.2337/diacare.19.3.257.
    1. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J. 1992;6(11):2905–2914.
    1. Di Mario U, Pugliese G. 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia. 2001;44(6):674–692. doi: 10.1007/s001250051676.
    1. Udupa AS, Nahar PS, Shah SH, Kshirsagar MJ, Ghongane BB. Study of comparative effects of antioxidants on insulin sensitivity in type 2 diabetes mellitus. J Clin Diagn Res. 2012;6(9):1469–1473.
    1. Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha- lipoic acid: a randomized double-blinded placebo-controlled study. Asia Pac J Clin Nutr. 2012;21(1):12–21.
    1. de Oliveira AM, Rondó PH, Luzia LA, D’Abronzo FH, Illison VK. The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Res Clin Pract. 2011;92(2):253–260. doi: 10.1016/j.diabres.2011.02.010.
    1. Santos JM, Kowluru RA. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci. 2011;52(12):8791–8798. doi: 10.1167/iovs.11-8203.
    1. Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vom Hagen F, Nawroth P, Brownlee M, Hammes HP. Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia. 2006;49(5):1089–1096. doi: 10.1007/s00125-006-0174-y.
    1. Haritoglou C, Gerss J, Hammes HP, Kampik A, Ulbig MW, RETIPON Study Group Alpha-lipoic acid for the prevention of diabetic macular edema. Ophthalmologica. 2011;226(3):127–137. doi: 10.1159/000329470.
    1. Nebbioso M, Federici M, Rusciano D, Evangelista M, Pescosolido N. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes Technol Ther. 2012;14(3):257–263. doi: 10.1089/dia.2011.0172.
    1. Yi X, Xu L, Hiller S, Kim HS, Nickeleit V, James LR, Maeda N. Reduced expression of lipoic acid synthase accelerates diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):103–111. doi: 10.1681/ASN.2011010003.
    1. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int. 2005;67(4):1371–1380. doi: 10.1111/j.1523-1755.2005.00214.x.
    1. Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M, Urich H, Wahl P, Ziegler R, Tritschler H, Halliwell B, Nawroth PP. alpha- Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med. 1999;26(11–12):1495–1500. doi: 10.1016/S0891-5849(99)00011-8.
    1. Cicek M, Yıldırır A, Okyay K, Yazici AC, Aydinalp A, Kanyilmaz S, Muderrisoglu H. Use of alpha-lipoic acid in prevention of contrast- induced nephropathy in diabetic patients. Ren Fail. 2013;35(5):748–753. doi: 10.3109/0886022X.2013.790298.
    1. Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU, Kim SB, Park JS. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol. 2007;27(1):70–74. doi: 10.1159/000099035.
    1. Morcos M, Borcea V, Isermann B, Gehrke S, Ehret T, Henkels M, Schiekofer S, Hofmann M, Amiral J, Tritschler H, Ziegler R, Wahl P, Nawroth PP. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract. 2001;52(3):175–183. doi: 10.1016/S0168-8227(01)00223-6.
    1. Heinisch BB, Francesconi M, Mittermayer F, Schaller G, Gouya G, Wolzt M, Pleiner J. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest. 2010;40(2):148–154. doi: 10.1111/j.1365-2362.2009.02236.x.
    1. Chen SA, Chen HM, Yao YD, Hung CF, Tu CS, Liang YJ. Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products. Eur J Pharm Sci. 2012;47(5):875–883. doi: 10.1016/j.ejps.2012.08.018.
    1. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20(3):369–373. doi: 10.2337/diacare.20.3.369.
    1. Pop-Busui R, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, Feldman EL. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia. 2013;56(8):1835–1844. doi: 10.1007/s00125-013-2942-9.
    1. Ziegler D. Diagnosis and mangement of diabetic peripheral neuropathy. Diabet Med. 1996;13(suppl 1):S34–S38.
    1. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49(1):229–239. doi: 10.1212/WNL.49.1.229.
    1. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study) Diabetologia. 1995;38(12):1425–1433. doi: 10.1007/BF00400603.
    1. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31(3):171–179. doi: 10.1080/10715769900300721.
    1. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22(8):1296–1301. doi: 10.2337/diacare.22.8.1296.
    1. Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med. 1999;16(12):1040–1043. doi: 10.1046/j.1464-5491.1999.00190.x.
    1. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D, SYDNEY Trial Study Group The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770–776. doi: 10.2337/diacare.26.3.770.
    1. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370. doi: 10.2337/dc06-1216.
    1. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–2060. doi: 10.2337/dc11-0503.
    1. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114–121. doi: 10.1111/j.1464-5491.2004.01109.x.
    1. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic neuropathy in patients with diabetes: A meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. doi: 10.1155/2012/456279.
    1. Bertolloto F, Massome A. Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. Drugs. 2012;12:29–34.
    1. Vasudevan D, Naik MM, Mukaddam QI. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. Results of a pilot study. Ann Indian Acad Neurol. 2014;17:19–24. doi: 10.4103/0972-2327.128535.
    1. Patel N, Mishra V, Patel P, Dikshot RK. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabetes Metab Disord. 2014;13:62. doi: 10.1186/2251-6581-13-62.
    1. Bresciani E, Busi A, Bazzigaluppi E, Balestere G. Insulin autoimmune syndrome induced by α lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011;34:e146. doi: 10.2337/dc11-0600.
    1. Mooradian AD, Haas MJ. Glucose-induced endoplasmic reticulum stress is independent of oxidative stress: a mechanistic explanation for the failure of antioxidant therapy in diabetes. Free Radic Biol Med. 2011;50:1140–1143. doi: 10.1016/j.freeradbiomed.2011.02.002.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する